(Total Views: 566)
Posted On: 08/21/2020 2:02:22 PM
Post# of 155002
Re: jerseylong #51153
Bingo... Couple that with the supply issues with RT-PCR reagents, the horrible failure rate of anti-gen/body tests.. if you have a test that can give a full diagnostic readout of what's abnormal and to what degree, you don't need confirmation of viral DNA, or antigens, or Antibodies... You get a glimpse into the likely future of the progression that patient will face. IncellDX and CytoDyn are completely hand-in-glove as far as CCR5 is concerned.
Dr. BP could have chosen a few different compounds for his CCR5 needs, but he chose LLmab, and he chose it for a reason. That profound fact seems lost on many here.
Dr. BP could have chosen a few different compounds for his CCR5 needs, but he chose LLmab, and he chose it for a reason. That profound fact seems lost on many here.
Quote:
CYDY & IncellDX are tightly intertwined where leronlimab is concerned. I would think the OWS letters would concern ramp up of production for both drug and kits. BP keeps saying he's a kit company and those kits are the invaluable diagnostics to help correctly administer the drug.
Really a home run partnership for both companies
(9)
(0)
